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Objective: Duchenne Muscular Dystrophy (DMD) is a rare progressive disease, which is 
often diagnosed in early childhood, and leads to considerably reduced life-expectancy; due 
to its rarity, research literature and patient numbers are limited. To fully characterise the 
natural history, it is crucial to obtain appropriate estimates of the life-expectancy and 
mortality rates of patients with DMD. 
Methods: A systematic review of the published literature on mortality in DMD up until July 
2020 was undertaken, specifically focusing on publications in which Kaplan-Meier (KM) 
survival curves with age as a time-scale were presented. These were digitised and individual 
patient data (IPD) reconstructed. The pooled IPD were analysed using the Kaplan-Meier 
estimator and parametric survival analysis models. Estimates were also stratified by birth 
cohort. 
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Results: Of 1177 articles identified, 14 publications met the inclusion criteria and provided 
data on 2283 patients, of whom 1049 had died. Median life-expectancy was 22.0 years (95% 
CI: 21.2, 22.4). Analyses stratifying by three time-periods in which patients were born 
showed markedly increased life-expectancy in more recent patient populations; patients 
born after 1990 have a median life-expectancy of 28.1 years (95% CI 25.1, 30.3). 
Conclusions: This paper presents a full overview of mortality across the lifetime of a patient 
with DMD, and highlights recent improvements in survival. In the absence of large-scale 
prospective cohort studies or trials reporting mortality data for patients with DMD, 
extraction of IPD from the literature provides a viable alternative to estimating life-
expectancy for this patient population. 
Keywords: Duchenne Muscular Dystrophy, DMD, life-expectancy, survival, mortality, rare 
diseases  
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1. Introduction 
Duchenne Muscular Dystrophy (DMD) is an X-linked, muscle degeneration disease nearly 
exclusively affecting males. It is a rare disease with a global prevalence of 1 in 3,500-5,000 
male births.
1
 Although corticosteroids are the mainstay treatment, there is currently no 
cure. In order to be reimbursed by health agencies, companies that develop new treatments 
need to show cost-effectiveness, which requires accurate modelling of the disease’s natural 
history, including mortality. 
DMD mortality has been published in isolation across different countries, sources and time 
periods, typically representing the experience of a single practice or selective population. 
Previous estimates of life-expectancy have been reported in the literature as 25 years,
2,3
 
while in more recent years this has increased to 31.7 (95% confidence interval (CI): 27.4, 
36.0)
4
. Many studies report trends of increasing life-expectancy with time.
1,5-7
 
A systematic review was recently conducted to obtain a single estimate of life-expectancy of 
29.9 years (95% CI: 26.5, 30.8) in ventilated patients with DMD.
8
 While the review provides 
an excellent summary of the published literature, survival across the whole disease 
pathway, rather than just the median, is needed to appropriately characterise a natural 
history model. 
This paper therefore aims to extend beyond these single summary estimates of life-
expectancy and provide comprehensive survival probabilities/mortality rates at different 
ages. This was achieved by performing a systematic review of the published literature on 
DMD life-expectancy, reconstructing individual patient data (IPD) and calculating pooled 








2.1. Systematic review 
A systematic review was performed on PubMed on 31 July 2020 and publications on DMD 
mortality prior to this date were identified. The following search terms were used: 
1. “Duchenne Muscular Dystrophy” OR “DMD” 
2. “Survival” OR “Mortality” OR “Death” OR “Life Expectancy” 
3. 1. AND 2. 
The citations of a subset of the results, which represented systematic reviews and/or meta-
analyses, were also reviewed for inclusion. The additional search terms were included for 
this review: 
4. “Systematic review” OR “Meta-analysis” 
5. 3. AND 4. 
Searches 3 and 5 were used to conduct the review. There were no exclusions based on 
region, language or time. Only full texts which were freely available to the Universities of 
Leicester and Sheffield were included in the review. The publications were required to 
report at least one Kaplan-Meier (KM) curve for survival in patients with DMD, which was 
generally confirmed by papers reporting genetic diagnosis. The KM curve had to be 
calculated as all-cause survival, with age as a timescale. Finally, the reported KM curve had 
to be able to be digitised, requiring the number of patients at risk to be reported as well as 
being of suitable digital quality. Where KM curves were stratified by a covariate, the number 
of patients in each stratum had to be reported, since these curves must be digitised 
separately. 
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The review was restricted to all-cause mortality, in order to ensure the outcome was 
comparable across studies and it was assumed that most deaths in these patients would be 
related to DMD. Age was chosen as the timescale as this provided clinically meaningful 
survival estimates and, for example, did not require knowledge of age of diagnosis. 
If multiple KM curves were presented in a single paper relating to the same DMD 
population, all were digitised for comparison, and a joint decision was made by the authors 
as to which data to include in the analysis, prioritising curves including the highest number 
of patients and curves of higher digital quality. 
The review was carried out according to PRISMA guidelines for conducting a systematic 
review.
9
 Two authors conducted the review separately and discussed any discrepancies. The 
quality of the papers included was assessed using the Joanna Briggs Institute (JBI) Critical 
Appraisal tool for case series, since the population consists exclusively of patients with 
DMD;
10
 if studies were assessed by the tool as being at risk of bias, the methods were 
repeated with these studies excluded as a sensitivity analysis. 
2.2. IPD extraction 
The KM curves for each strata were digitised using WebPlotDigitizer.
11
 The IPD were 
reconstructed using the approach of Guyot et al,
12
 which was developed and implemented 
using the ipdfc command
13
 in Stata. Many studies reported KM curves split by levels of a 
discrete covariate. In these instances, each curve was digitised separately and the data from 
the curves were pooled. Digitisation of curves was also conducted by two authors, with 
summary statistics (medians or earlier quantiles if not reached and survival probabilities) 
and reproduced graphs being compared to the original study graph to ensure a suitable 
degree of accuracy. If the digitised number of patients or deaths was greater or less than 
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the original number by 10% for both authors, the study was deemed insufficiently digitised 
and excluded from analysis. 
2.3. Pooled data analysis 
Two approaches to the data analysis were adopted; a non-parametric overview of DMD 
mortality and a parametric calculation of mortality rates. The data were analysed firstly as a 
combined cohort and secondly by stratifying the pooled IPD into three cohorts based on the 
period of birth for each study: pre 1970, 1970-1990 and post 1990. If period of birth for each 
group of patients was not explicitly reported then it was approximated as the average age at 
recruitment subtracted from the midpoint of the period of recruitment. The birth cohorts 
were defined to evenly split patients and investigate trends in life-expectancy over time. The 
most recent birth cohort is likely to contain only steroid-using patients, as steroid use has 
been the mainstay of treatment since the 1990s. The cohort analysis is also likely to 
represent a comparison of ventilated and non-ventilated patients, since ventilation was only 
introduced in many clinical settings in the 1990s.
8 
A non-parametric KM curve was used to summarise the survival estimates of the pooled 
sources. Median survival was compared in the pooled dataset and across birth cohorts. 
A parametric survival model with a piecewise-constant hazard function was estimated with 
cut-points first every five years and then every year, from age 0 to the maximum observed 
death. This covered follow-up from possible diagnosis at birth to a time horizon of the 
oldest observed death in the dataset. This model assumes that the rate of death of patients 
is the same for all ages within a time-period, while allowing rates of death to differ across 
time-periods. Since the rate of death in young patients is likely to be very different to the 
rate of death in older patients, this model choice is preferred to, for example, an 
exponential model which assumes the same rate of death across all ages. Rates for patients 
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older than 40 were grouped and averaged, since patient numbers were small after this time. 
A normally distributed frailty term for study was incorporated into the model on the log-
hazard scale to account for potential between-study variability.
14
 The frailty term allows the 
precise estimates of mortality within each study to differ, by introducing unobserved 
variation between studies. It is included because the studies cover a range of global 
populations with follow-up over different calendar periods. The choice of parametric model 
enables smoother results with interval-specific mortality, which are directly applicable to 
health economic analysis. Proportional hazards were assumed in secondary analysis 
between birth cohorts; the assumption was assessed using log-log plots of survival in each 
cohort against log time. Stata 16 was used for statistical analysis. 
2.4 Data availability 
The data used in this review are reconstructed IPD and so do not directly correspond to real 
patients. The full reconstructed dataset is available upon request. 
2.5 Standard Protocol Approvals, Registrations, and Patient Consents 
No protocol or ethical approval was required for this work, as the data are already 
anonymised and in the public domain. 
 
3. Results 
3.1. Systematic review 
The flowchart of the systematic review is shown in Figure 1. Of 1177 results from the initial 
search described in Section 2.1, 21 papers contained at least one appropriate KM curve. 2 
were excluded for not being able to be digitised. 2 more were excluded for a potential 
overlap of patients - in both instances, a larger study was conducted by the same author in 
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the same location that was eligible for inclusion and so the smaller study was excluded. 
Thus, 17 papers remained eligible for digitisation. Following the supplementary review of 
references in systematic reviews of DMD mortality, a further paper was identified as 
appropriate for inclusion from Landfeldt et al’s review.
8
 This brought the final total number 
of papers to 18. 
18 papers were eligible for digitising,
1-7, 15-25
 contributing 3131 total patients and 1250 total 
deaths. Table 1 contains the key details of these papers. The studies were performed 
worldwide including Europe, USA, Chile and Japan and covered a range of birth, clinic 
admittance and death cohorts, with the earliest being born in 1954 and the latest in the late 
2000s. Table 2 details how studies were assigned to each birth cohort. 
The results of the JBI tool are displayed in Table 3. Overall, papers were of fairly high quality; 
the most common issue was with papers' exclusion criteria (criteria C5). Two papers 
performed slightly more poorly than the rest; one due to poor reporting of methods of 
diagnosis and analysis
19
 and the other due to the paper being an editorial letter and 
providing insufficient detail.
25 
3.2. IPD extraction 
Of the KM curves from the 18 papers, 4 were not adequately reproduced by either of the 
two authors.
2,6,15,20
 This was because the number of deaths in each level of the curve were 
not reported, and so the algorithm was much less accurate in data reconstruction. These 
studies were excluded from the analysis. In addition, one paper only contained information 
on the number of deaths for some of the covariate levels;
17
 IPD from these curves were 
included, but not from the other curves in this paper as deaths were again overestimated by 
both authors. 
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The digitised data from the remaining 14 studies yielded 2283 patients and 1050 deaths 
(compared to 1049 in the original - one paper produced one more digitised death than was 
reported
16
). The digitised data gave broadly very similar KM curves to those presented in 
the publications. The algorithm is least accurate when reproducing ages at death at the end 
of follow-up, so KM curve replication was poorest in the tails of some studies
1,5,22
. In these 
studies a small percentage of deaths were observed at late follow-up. Median survival was 
also compared between original and reproduced curves, and was consistently reproduced 
and is presented in Table 4. 
3.3. Pooled data analysis 
The total follow-up time was 40274 patient years with a maximum age of 44.4 years old. 
Median survival age, calculated using the Kaplan-Meier estimator, was 22.0 years (95% CI: 
21.2, 22.4). Survival probabilities at 10, 20, 30 and 40 years were 99.8% (95% CI: 99.4%, 
99.9%), 59.5% (95% CI: 56.9%, 61.9%), 26.1% (95% CI: 23.5%, 28.8%) and 13.3% (95% CI: 
9.8%, 17.3%), respectively. Figure 2A illustrates the survival probabilities from the digitised 
data. The at-risk table shows the number of patients at risk at the beginning of the interval 
and the number in parentheses is the number of deaths that occur within the interval. 
Secondary analysis suggested an improvement in life-expectancy over time. The median 
survival age from the pre 1970 birth cohort was 18.3 years (95% CI: 18.0, 18.9) compared to 
24.0 years in the 1970-1990 birth cohort (95% 22.8, 25.0) and 28.1 years in the post 1990 
birth cohort (95% 25.1, 30.3). Survival split by birth cohort is presented in Figure 2B. Log-log 
plots of survival in each cohort were approximately parallel indicating that proportional 
hazards was an appropriate assumption.  
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5-year mortality rates per 1,000 person-years (PYs) with CIs from the piecewise exponential 
model are given in Table 5, adjusted for between study variability by including a shared 
frailty term. Mortality is averaged over patients older than 40 as data are sparse. 
Mortality is very low in patients with DMD aged between 0-10, and increases with age - in 
the combined analysis it was estimated that for every 1,000 patients aged 20-25, 86 would 
die each year, increasing to 336 each year for those aged over 40. Uncertainty increases as 
patients age, as more patients die or are censored so there are fewer patients from which to 
estimate mortality rates. Mortality rates were much higher in the birth cohort from before 
1970 compared to the later cohorts; 265 of every 1000 patients with DMD aged 25-30 that 
were born before 1970 died every year, compared to just 27.6 a year for every 1000 born 
after 1990. 
As a sensitivity analysis, the studies that performed more poorly in the JBI tool
19,25
 were 
removed and non-parametric analysis was re-run. This yielded an overall median survival of 
21.4 years (95% CI: 20.8, 22.2), and median survival estimates of 18.1 years (95% CI: 17.8, 
18.7), 22.9 years (95% CI: 22.0, 24.0) and 28.1 years (95% CI: 25.1, 30.3) for patients born 
before 1970, between 1970-1990 and after 1990 respectively. These estimates are very 





Our work has provided a set of accessible age-specific all-cause mortality rates that can be 
incorporated into the natural history modelling of DMD. This is particularly important for 
economic decision modelling evaluating future health technologies/treatments, not just in 
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DMD but also as a framework for other rare diseases.
26
 Natural history models rely on 
reliable estimates of mortality throughout the disease pathway, and while the analysis is not 
without limitation, the only previous meta-analytic work of this nature provides a median 
estimate of survival
8
 which while useful is not sufficiently granular for natural history 
modelling. 
Early mortality is negligible, both in the overall dataset and in each birth cohort. Median 
survival in the overall dataset was 22.0 years (95% CI: 21.2, 22.4), but survival rates have 
increased over time, with a median survival of 28.1 years (95% CI: 25.1, 30.3) in patients 
born after 1990. These results are consistent with other recent work.
8
 Moreover, these 
estimates may slightly underestimate median survival in more recently diagnosed patients, 
as some of the papers that were excluded from the final analysis at the data reconstruction 
phase had KM curves of patients that either had not reached median survival by age 30
15
 or 
had median estimates greater than 30 years of age.
6,17 
Our work is comparable to Landfeldt et al's review.
8
 The search terms were almost identical, 
and all papers included in their study were identified by our search. However, 6 of our 18 
papers identified by the systematic review were not included in their review, which could be 
due to slightly differing search terms
2
 or differing exclusion criteria of DMD diagnosis
18
. 
While our paper relied only upon a clinical, rather than genetic, diagnosis, the two studies 
produced very similar results, as did a sub-analysis of our cohort excluding studies that were 
not included in Landfeldt et al’s review. Median survival was comparable between the 
reviews, with both identifying a marked improvement in life-expectancy over time. 
However, our paper also provides age-specific estimates of survival and mortality rates over 
the whole trajectory of a patient with DMD, allowing natural history models to incorporate 
mortality representative of the global population of patients with DMD. 
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This study highlights the importance of making the most of available data, an issue 
particularly pertinent to rare diseases such as DMD. Appropriate estimates of life 
expectancies are also important for other reasons; for instance, a better understanding of 
life-expectancies and estimates of age-specific mortality for patients with DMD could help 
with disease management and planning of service provision, as well as counselling for 
parents and carers. 
However, there are limitations with our work. Firstly, access to the full IPD in the studies 
would be most desirable, to avoid unnecessary study exclusion caused by a lack of 
knowledge of strata sample sizes and eliminate any errors caused by data extraction. This 
study does provide generalisable methodology for situations where IPD are unavailable. We 
were also limited by restricted literature access and could not review 86 of the 1177 
identified articles. Additionally, the assignment of patients to birth cohorts was not always 
straightforward, and knowledge of the exact period of birth of patients in each study would 
have been preferable. 
A further complication from the lack of IPD is that all patients are assumed to have been 
followed up from birth. This introduces the possibility of immortal time bias in studies, since 
it is an unintentional condition to survive beyond a certain point in order to be included in 
these studies – in other words, the sickest patients that die before being recruited to a study 
are ignored, and so the population analysed may be slightly healthier than the true 
underlying DMD population. The impact of this is probably minimal, since studies that did 
report average ages at recruitment generally reported fairly young (<10 years of age) 
recruitment ages, but it is difficult to assess what impact, if any, this possible bias may have 
on the final results. 
Further work could be undertaken investigating the impact of other covariates, such as 
geographic location (which could affect standard of care), information on steroid treatment 
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(such as type, duration of treatment, age at initiation) and ventilator use. Although 
interesting and pertinent questions, this would require a high level of harmonisation 
between studies. Our birth cohort assignment should stratify between patient populations 
before and after steroid use became mainstay (following the publication of a number of 
trials in the late 1980s and early 1990s reporting beneficial effects of corticosteroid 
therapy
27
), but this obviously does not guarantee a clear comparison of steroid and non-
steroid users. The study populations vary globally and ethnically, with studies from North 
and South America, Europe and Asia. Whilst an in-depth sub-analysis by region would be 
desirable, it is a reflection of the rarity of the disease that these sources must be pooled 
together to obtain more precise estimates of survival rates and probabilities. 
Extensions of the work could be to supplement with, and compare to, results from the 
Cooperative International Neuromuscular Research Group (CINRG). CINRG have conducted 
an international natural history study on 440 patients.
28
 This included prospectively 
collecting mortality data,
29
 but to date no mortality analysis has been published. 
Comparison with this study would enable validation of these results in a US population, as 
only 5 of the 14 included studies contained patients from the USA. Similar work could be 
completed in the UK by linking to large scale population linked electronic health record data, 
for example the Clinical Practice Research Datalink (CPRD).  This would have the additional 
advantage of minimising selection effects due to cohorts often being established at 
specialist centres. 
We make several recommendations based on our findings. This work highlights 
improvements in survival for patients with DMD over time, as standards of care have 
increased. We emphasise the need for mortality collection to be considered in the design 
stage, especially in natural history/registry studies. We strongly advocate the need to 
include mortality data in any natural history model, in order to accurately represent the 
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whole natural history, whether IPD are available or not. When they are not available, we 
recommend using the DMD mortality statistics provided here, or obtaining them through 
other means (such as a review of relevant records or similar systematic review of mortality 
rates).  
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Figure 1: Flow of identified DMD mortality articles on PubMed. 
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Table 1: Description of the 18 studies eligible for digitisation. 
 
*Study was entirely excluded from final analysis for insufficiently accurate IPD. 
†
Study was partly excluded from final analysis for insufficiently accurate IPD. 
Author Year Region Time Period N Deaths Covariate(s) Birth Cohort 
Wittlieb-Weber
15
* 2020 USA and Canada Admitted 2005-2015 407 27 None Post 1990 
San Martin
1 





2018 Greater Cleveland, USA Visited clinic 2003-2015 57 27 Genetic mutation Post 1990 
van den Bergen
5 
2014 Netherlands Born 1961-2006 629 139 Birth cohort Pre 1970, Post 1990 
Kieny
6
* 2012 Nantes, France Visited clinic 1981-2011 119 55 Ventilation; Birth cohort Pre 1970, 1970-1990 
Rall
16 
2012 Wuerzburg, Germany Born 1970-1980 66 45 Ventilation 1970-1990 
Matsumura
17† 2011 Osaka, Japan Visited clinic 1977-2010 286 177 Period/ventilation Pre 1970, 1970-1990, Post 1990 
Fraser
18 
2011 Leeds, UK Visited clinic 1987-2010 192 93 None 1970-1990 
Bach
19 
2011 New Jersey, USA Visited clinic 2002-2011 101 45 None 1970-1990 
Gordon
20
* 2011 Nova Scotia, Canada Visited clinic 1977-2006 44 13 Bisphosphonate use Pre 1970, 1970-1990 
Ishikawa
7 
2010 Yakumo, Japan Visited clinic 1964-2010 187 113 Period/ventilation Pre 1970, 1970-1990, Post 1990 
Kohler
21 
2009 Zurich, Switzerland Enrolled 1999-2006 43 3 None 1970-1990 
Mochizuki
2
* 2008 Hasuda, Japan Admitted 1995-2007 74 11 Mental difficulty 1970-1990 
Eagle
3 
2002 Newcastle, UK Visited clinic 1967-2002 183 168 Period/ventilation Pre 1970, 1970-1990 
Gomez-Merino
22 
2002 New Jersey, USA 
 
Visited clinic 1983-2002 91 34 Protocol access 1970-1990 
Phillips
23 
2001 Liverpool, UK Visited clinic 1986-1999 58 37 None 1970-1990 
Boland
24 
1996 Minnesota, USA Born 1953-1983 33 17 None Pre 1970 
Yasuma
25 
1996 Suzuka, Japan Visited clinic 1980-1995 99 80 Ventilation Pre 1970, 1970-1990 
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Table 2: Assignment of KM curves to birth cohorts. 
 
*Study or curve was excluded from final analysis for insufficiently accurate IPD. 
  
Study Year Covariate Birth Period Recruitment 
Period 
Recruitment Age Birth Cohort 
Wittlieb-Weber
15
* 2020 - Not reported 2005-2015 Mean = 10.2 Post 1990 
San Martin
1 
2018 - Not reported 1993-2013 Mean = 6.1 Post 1990 
Wang
4 
2018 Pooled Not reported 2003-2015 Mean = 18.1 Post 1990 
van den Bergen
5 
2014 Birth 1 1961-1974   Pre 1970 
 
 Birth 2 1980-2006   Post 1990 
Kieny
6
* 2012 Birth 1 1955-1970   Pre 1970 
 
 Birth 2 1970-1994   1970-1990 
Rall
16 
2012 Pooled 1970-1980   1970-1990 
Matsumura
17 
2011 No vent 1 Not reported 1977-1984 Not reported Pre 1970 
  No vent 2 Not reported 1984-2010 Not reported 1970-1990 
 
 Vent 1* Not reported 1984-1993 Not reported 1970-1990 
 
 Vent 2* Not reported 1994-2003 Not reported 1970-1990 
 
 Vent 3* Not reported 2004-2010 Not reported Post 1990 
Fraser
18 
2011 - Not reported 1987-2010 Mean = 11.8 1970-1990 
Bach
19 
2011 - Not reported 2002-2011 Not reported 1970-1990 
Gordon
20
* 2011 No bisphos Not reported 1977-1997 Not reported 1970-1990 
 
 Bisphos Not reported 1997-2007 Median = 12 Post 1990 
Ishikawa
7 
2010 NIV Not reported 1991-2010 Not reported Post 1990 
  Tracheotomy Not reported 1984-1991 Not reported 1970-1990 
  No vent 1 Not reported 1991-2010 Not reported 1970-1990 
  No vent 2 Not reported 1984-1991 Not reported Pre 1970 
  No vent 3 Not reported 1964-1984 Not reported Pre 1970 
Kohler
21 
2009 - Not reported 1999-2006 Mean = 15.3 1970-1990 
Mochizuki
2
* 2008 Pooled Not reported 1995-2007 Not reported 1970-1990 
Eagle
3 
2002 Ventilation Not reported 1990-2002 Not reported 1970-1990 
  No vent 1 Not reported 1990-2002 Not reported 1970-1990 
  No vent 2 Not reported 1980-1989 Not reported Pre 1970 
  No vent 3 Not reported 1970-1979 Not reported Pre 1970 
  No vent 4 Not reported 1960-1969 Not reported Pre 1970 
Gomez-Merino
22 
2002 Pooled Not reported 1983-2002 Not reported 1970-1990 
Phillips
23
 2001 - Not reported 1986-1999 Mean = 12 1970-1990 
Boland
24 
1996 - 1954-1982   Pre 1970 
Yasuma
25 
1996 No vent Not reported 1980-1987 Not reported Pre 1970 
  CR vent Not reported 1987-1991 Not reported Pre 1970 
  NIPPV vent Not reported 1992-1995 Not reported 1970-1990 
 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.  
 
Table 3: Results from the JBI tool for assessing bias. 
 
*Study was entirely excluded from final analysis for insufficiently accurate IPD. 
†
Study was partly excluded from final analysis for insufficiently accurate IPD. 
C1: Were there clear criteria for inclusion in the case series? 
C2: Was the condition measured in a standard, reliable way for all participants included in the case series? 
C3: Were valid methods used for identification of the condition for all participants included in the case series? 
C4: Did the case series have consecutive inclusion of participants? 
C5: Did the case series have complete inclusion of participants? 
C6: Was there clear reporting of the demographics of the participants in the study? 
C7: Was there clear reporting of clinical information of the participants? 
C8: Were the outcomes or follow up results of cases clearly reported? 
C9: Was there clear reporting of the presenting site(s)/clinic(s) demographic information? 
C10: Was statistical analysis appropriate? 
  
Paper Year C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 
Wittlieb-Weber
15
* 2020 Yes Yes Yes Yes No Yes Yes Yes Yes Yes 
San Martin
1 
2018 Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes 
Wang
4 
2018 Yes Yes Yes Yes No Yes Yes No Yes Yes 
van den Bergen
5 
2014 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Kieny
6
* 2012 Yes Yes Yes Yes No Yes Yes No Yes Yes 
Rall
16 
2012 Yes Yes Yes Yes Yes Yes Yes No Yes Yes 
Matsumura
17† 
2011 Yes Yes Yes Yes No Yes Yes Yes Yes Yes 
Fraser
18 
2011 Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes 
Bach
19 
2011 Yes Unclear Unclear Yes No Yes Yes Yes Yes No 
Gordon
20
* 2011 Yes Yes Yes Yes No Yes Yes No Yes Yes 
Ishikawa
7 
2010 Yes Yes Yes Yes No Yes Yes Yes Yes Yes 
Kohler
21 
2009 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Mochizuki
2
* 2008 Yes Yes Yes Yes Yes No Yes No No Yes 
Eagle
3 
2002 Yes Yes No Yes No Yes Yes Yes Yes Yes 
Gomez-Merino
22 
2002 Yes Yes Yes Yes No Yes Yes Yes Yes Yes 
Phillips
23 
2001 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Boland
24 
1996 Yes Yes Yes Yes No Yes Yes Yes Yes Yes 
Yasuma
25 
1996 Yes Unclear Unclear Yes Yes No No Yes No Yes 
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Table 4: Original and reproduced statistics from each study. 
Study Year Covariate n (deaths) Median S(20) 
   Orig. Rep. Orig. Rep. Orig. Rep. 
Wittlieb-Weber
15




 0.887 0.908 
San Martin
1 
2018 - 462 (166) 462 (166) 20.271 20.278 0.518 0.519 
Wang




 0.918 0.889 
 
 Other mutation 48 (24) 48 (24) 31.919 32.083 0.892 0.948 
van den Bergen
5 
2014 Born 1961-1974 293 (98) 293 (98) 17.969 18.087 0.181 0.177 
 
 Born 1980-2006 336 (41) 336 (41) 29.008 29.070 0.832 0.831 
Kieny
6
* 2012 Born 1955-1970 
119 (55) 119 (84) 
25.753 25.743 0.930 0.930 
 
 Born 1970-1994 40.964 40.964 1.000 1.000 
Rall
16 
2012 No ventilation 
66 (45) 66 (46) 
18.943 19.051 0.272 0.273 
  Ventilation 26.943 20.057 0.819 0.886 
Matsumura
17 
2011 No vent, 1977-1984 33 (33) 33 (33) 17.501 17.575 0.396 0.394 




204 (95) 204 (148) 




32.846 33.052 0.949 0.949 






 0.966 0.971 
Fraser
18 
2011 - 192 (93) 192 (93) 21.443 21.550 0.593 0.607 
Bach
19 
2011 - 101 (45) 101 (45) 28.000 28.094 0.894 0.895 
Gordon
20
* 2011 No bisphosphonates 
44 (13) 39 (39) 
20.948 20.996 0.608 0.607 
 
 Bisphosphonates 26.942 24.013 0.850 0.818 
Ishikawa
7 
2010 NIV, 1991-2010 88 (17) 88 (17) 39.603 39.561 0.972 0.966 
  Tracheo, 1984-1991 24 (21) 24 (21) 28.808 29.693 0.834 0.826 
  No vent, 1991-2010 8 (8) 8 (8) 21.939 20.132 0.665 0.625 
 
 No vent, 1984-1991 11 (11) 11 (11) 17.173 17.149 0.352 0.357 
 
 No vent, 1964-1984 56 (56) 56 (56) 18.084 18.036 0.088 0.091 
Kohler
21 
2009 - 43 (3) 43 (3) 35.044 35.010 1.000 1.000 
Mochizuki
2
* 2008 Mental retardation 
74 (11) 74 (22) 
25.925 25.877 0.915 0.913 




 1.000 1.000 
Eagle
3
 2002 Vent, 1990-2002 24 (9) 24 (9) 26.206 26.165 0.892 0.830 
  No vent, 1990-2002 33 (33) 33 (33) 19.025 18.961 0.338 0.333 
 
 No vent, 1980-1989 68 (68) 68 (68) 18.678 18.710 0.385 0.382 
  No vent, 1970-1979 49 (49) 49 (49) 17.983 17.849 0.216 0.245 
 
 No vent, 1960-1969 9 (9) 9 (9) 14.334 14.337 0.000 0.000 
Gomez-Merino
22 





  Access to protocol 34 (3) 34 (3) 28.778 28.912 0.802 0.803 
Phillips
23
 2001 - 58 (37) 58 (37) 21.500 21.454 0.727 0.732 
Boland
24 
1996 - 33 (17) 33 (17) 22.698 22.573 0.515 0.546 
Yasuma
25 
1996 No vent, 1980-1987 65 (65) 65 (65) 20.092 20.122 0.507 0.508 
  CR, 1987-1991 7 (7) 7 (7) 21.034 21.007 0.710 0.714 
  NIPPV, 1992-1995 27 (8) 27 (8) 30.422 30.478 0.916 0.944 
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*Study or curve was excluded from final analysis for insufficiently accurate IPD. 
†
Median not reached so compared p(25). 
‡
Median and p(25) not reached so compared p(10). 
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Table 5: 5-year mortality rates per 1,000 PYs, combined and stratified, with 95% CIs. 
 
 
   Age    Combined Pre 1970 1970-1990 Post 1990 
0-5 0.07 0.141 0.061 0.0148 
 
(0.00955, 0.513) (0.019, 1.05) (0.00814, 0.449) (0.00195, 0.111) 
 5-10  0.324 0.649 0.278 0.0678 
 
(0.115, 0.918) (0.223, 1.89) (0.0956, 0.808) (0.0226, 0.203) 
 10-15  11.9 24.2 10.4 2.53 
 
(8.09. 17.6) (15.4, 38.2) (6.57, 16.4) (1.50, 4.26) 
 15-20 66.9 148 63.4 15.5 
 
(46.7, 95.9) (96.2, 228) (41.2, 97.5) (9.43, 25.4) 
 20-25 85.5 232 99.5 24.3 
 
(59.3, 123) (149, 362) (64.4, 154) (14.9, 39.6) 
 25-30  87.7 275 118 28.7 
 
(58.7, 131) (171, 444) (74.2, 187) (17.2, 48.0) 
 30-35  84.4 265 113 27.6 
 
(51.9, 137) (152, 459) (66.2, 194) (15.4, 49.4) 
 35-40  71 244 104 25.5 
 
(35.5, 142) (116, 514) (50.3, 217) (11.9, 54.7) 
40+ 336 1250 536 131 
  (146, 773) (518, 3020) (225, 1280) (53.4, 318) 
Variance between studies = 0.442 (0.180, 0.991) in combined analysis. 
Variance between studies = 0.557 (0.246, 1.35) in stratified analysis. 
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